Serenas Lawsuit Amended to Remove Claim for 10,270,437 Shares or $5,546,035 as Against Experion Holdings Ltd

VANCOUVER, BC / ACCESSWIRE / August 6, 2019 / Experion Holdings Ltd. (“Experion” or the “Company”) (TSXV:EXP)(OTCQB:EXPFF) (Frankfurt: MB31), formerly Viridium Pacific Group Ltd., today reports with respect to the litigation launched by Stephen Serenas and Pacific Executive Capital Corp, previously reported by the Company on June 8, 2019. The Plaintiffs have filed an Amended Notice of Civil Claim with the BC Supreme Court that has removed the claim for 10,270,437 shares, or alternatively $5,546,035, as against Experion Holdings Ltd. and its wholly owned subsidiary, Experion Biotechnologies Inc. Accordingly, the Plaintiffs are no longer seeking an order for 10,270,437 shares, or alternatively $5,546,035, from either Experion Holdings Ltd. or Experion Biotechnologies Inc. (they continue to seek this relief from other defendants). By means of various allegations in the Amended Notice of Civil Claim, the Plaintiffs are continuing to pursue Experion Holdings Ltd. and Experion Biotechnologies Inc. for wrongful dismissal and other relief, including 149,625 restricted stock units. Experion Holdings Ltd. and Experion Biotechnologies Inc. intend to continue to vigorously defend against the remaining claims.

About Experion Holdings Ltd.

Experion Holdings Ltd. is the parent company of Experion Biotechnologies Inc., a Health Canada licensed cultivator and processor of Cannabis, based in Mission, BC; and EFX Laboratories Inc., a medical products production and clinical research company based in Calgary, AB.

Experion Holdings Ltd. is invested in a portfolio of products to address a wide spectrum of consumer needs’ including Medical, Adult-use, and Wellness and Therapeutic products.

Experion trades on the TSX Venture Exchange as a Tier 1 issuer under the symbol “EXP” on the OTCQB Venture under the symbol “EXPFF” and on the Frankfurt Stock Exchange under the symbol “MB31”

For further information, please visit the Company’s website www.experionwellness.com or join our Global Investor Forum on 8020 http://connects.company/ExperionEXP where you can read all press releases, get continued corporate information and interact with Investor Relations

Experion Holdings Ltd
Judy-Ann Pottinger, Investor Relations
Tel: (604) 617-5290
judy-ann@experionwellness.com

Disclosure

This press release contains forward-looking information within the meaning of Canadian securities laws. Although the Company believes that such information is reasonable, it can give no assurance that such expectations will prove to be correct.

Forward looking information is typically identified by words such as: believe, expect, anticipate, intend, estimate, forecast, postulate and similar expressions, or are those, which, by their nature, refer to future events. The Company cautions investors that any forward-looking information provided by the Company are not guarantees of future results or performance, and that actual results may differ materially from those in forward looking information as a result of various factors, including, but not limited to: the state of the financial markets for the Company’s equity securities; recent market volatility; the Company’s ability to raise the necessary capital or to be fully able to implement its business strategies; the risks identified in the Filing Statement, and other risks and factors that the Company is unaware of at this time. The reader is referred to the Filing Statement dated September 25, 2017 and/or the most recent annual and interim Management’s Discussion and Analysis for a more complete discussion of such risk factors and their potential effects, copies of which may be accessed through the Company page on SEDAR at www.sedar.com.

SOURCE: Experion Holdings Ltd.

View source version on accesswire.com:
https://www.accesswire.com/554771/Serenas-Lawsuit-Amended-to-Remove-Claim-for-10270437-Shares-or-5546035-as-Against-Experion-Holdings-Ltd

Staff

Recent Posts

PhotoPharmics Launches Largest Phototherapy Trial for Parkinson’s Disease

Pivotal Trial for Improving Overall Function and Quality of LifeSALT LAKE CITY--(BUSINESS WIRE)--#medicaldevices--PhotoPharmics, a pioneer…

5 hours ago

AARC Celebrates Introduction of the SOAR Act in the House of Representatives

Bill passage key to supplemental oxygen access and adequate reimbursementIRVING, TX / ACCESSWIRE / March…

8 hours ago

She Is Not Skipping a Beat, and Patients Are Noticing

NORTHAMPTON, MA / ACCESSWIRE / March 26, 2024 / Quest Diagnostics At Quest for 2…

8 hours ago

Innovaccer Launches AI Advisory Board to Drive Advances in Artificial Intelligence

Expanding its roster of technology leaders will enhance its ability to drive innovation and deliver…

11 hours ago

Virtual Second Opinions Save Over $8,700 Per Patient, New Analysis Finds

Third-party research confirms significant impact of specialty expertise on patients’ quality of life and costs…

11 hours ago